close

KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  271.98
-0.67 (-0.24%)
AAPL  311.08
+0.08 (0.03%)
AMD  494.57
+12.52 (2.60%)
BAC  62.86
-0.39 (-0.62%)
GOOG  356.83
-3.30 (-0.92%)
META  588.25
-0.52 (-0.09%)
MSFT  496.43
+8.97 (1.84%)
NVDA  219.44
+0.22 (0.10%)
ORCL  144.32
-0.06 (-0.05%)
TSLA  318.06
-3.49 (-1.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at /week.